Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
Status:
Recruiting
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is progressively common, and increases the risk of stroke five-fold.
Oral anticoagulation is the mainstay therapy; however, it increases the risk of bleeding.
Moreover, 30% with AF and at risk of stroke are not in relevant anticoagulation. The
randomized PROTECT-AF trial has demonstrated the superiority of left atrial appendage
occlusion (LAAO) as compared to warfarin for prevention of the combined endpoint of stroke,
major bleeding and cardiovascular mortality. However, studies comparing LAAO to therapy with
novel oral anticoagulants (NOAC) have not been carried out.
This study aims to assess the effect of left atrial appendage occlusion (LAAO) to reduce the
incidence of stroke, systemic embolism, major bleeding and all-cause mortality in patients
with atrial fibrillation (AF) and a prior ischemic stroke or transient ischemic attack (TIA).
Phase:
N/A
Details
Lead Sponsor:
University of Aarhus
Collaborators:
Aalborg Universitetshospital Aalborg University Hospital Aarhus University Hospital Haukeland University Hospital Helsinki University Central Hospital Karolinska University Hospital Odense University Hospital Sahlgrenska University Hospital, Sweden Turku University Hospital